Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Resuscytacja urazowa za pomocą pełnej krwi lub produktów grupy O o niskim mianie (TROOP)

18 września 2026 zaktualizowane przez: Jan O. Jansen, University of Alabama at Birmingham

The goal of this clinical trial is to compare the effectiveness of unseparated whole blood (referred to as Low-Titer Group O Whole Blood) and the separate components of whole blood (including red cells, plasma, platelets, and cryoprecipitate) in critically injured patients who require large-volume blood transfusions.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

Trauma is one of the leading causes of death in the United States, and disproportionately affects the young, killing those who might otherwise have lived long and productive lives. Injuries account for more years of potential life lost before age 75 than any other cause. Hemorrhage remains the most common cause of preventable death after injury, and blood transfusion is an essential part of treatment. Modern blood banking practices separate donated whole blood into components. The current standard of care in trauma transfusion is the balanced administration of equal numbers of units of blood components (packed red blood cells, plasma, and platelets), effectively attempting to reconstitute whole blood. A renewed approach to blood transfusion therapy in trauma is to use whole blood from the outset, which has not been separated. Compared with component therapy, whole blood offers several potential advantages, but there are only a small number of, mostly observational, studies comparing whole blood and component therapy, and they are very heterogeneous.

The TROOP trial will include injured adults with hemorrhagic shock anticipated to require massive blood transfusions, who will be randomized to receive either whole blood (LTOWB) or blood components. This will allow a direct comparison to see if one type of transfusion is more strongly associated with improved clinical outcomes over the other.

The knowledge gained from this clinical trial will transform the way in which massively bleeding trauma patients are transfused. The trial is exceedingly well positioned to improve mortality from trauma and reduce the number of preventable deaths resulting from hemorrhagic shock.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

1100

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Alabama
      • Birmingham, Alabama, Stany Zjednoczone, 35294
        • University of Alabama at Birmingham, UAB Hospital
    • California
      • Los Angeles, California, Stany Zjednoczone, 90033
        • Los Angeles County + University of Southern California (LAC + USC) Medical Center
    • Louisiana
      • New Orleans, Louisiana, Stany Zjednoczone, 70112
        • University Medical Center New Orleans LCMC Health
    • Maryland
      • Baltimore, Maryland, Stany Zjednoczone, 21201
        • University of Maryland Medical Center
    • Missouri
      • St Louis, Missouri, Stany Zjednoczone, 63110
        • Washington University School of Medicine
    • North Carolina
      • Winston-Salem, North Carolina, Stany Zjednoczone, 27157
        • Atrium Health Wake Forest Baptist
    • Ohio
      • Cincinnati, Ohio, Stany Zjednoczone, 45267
        • University of Cincinnati Medical Center
    • Oregon
      • Portland, Oregon, Stany Zjednoczone, 97239
        • Oregon Health and Sciences University Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Stany Zjednoczone, 19104
        • Penn Presbyterian Medical Center
    • Texas
      • Houston, Texas, Stany Zjednoczone, 77030
        • University of Texas Health Science Center Houston
      • San Antonio, Texas, Stany Zjednoczone, 78229
        • University of Texas Health San Antonio and University Health System
    • Washington
      • Seattle, Washington, Stany Zjednoczone, 98104
        • Harborview Medical Center
    • Wisconsin
      • Milwaukee, Wisconsin, Stany Zjednoczone, 53226
        • Froedtert Hospital

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

15 lat i starsze (Dziecko, Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Adult trauma patient (estimated age > 15 or weight > 50 kg, if age unknown)

  2. Patient taken to trauma center directly from scene

  3. Commencement of blood transfusion (PRBC, plasma or LTOWB), in pre-hospital or in-hospital setting

  4. Activation of site-specific Massive Hemorrhage Protocol or Massive Transfusion Protocol

  5. Traumatic injury with at least one of the following:

    1. Confirmed or suspected acute major bleeding
    2. Assessment of Blood Consumption (ABC) Score ≥2

Exclusion Criteria:

  1. Patients who have received, prehospital or in-hospital more than two units of LTOWB; the equivalent in components (two units of packed red blood cells and two units of plasma); or a combination of the two (more than one unit of LTOWB, one unit of packed cells, and one unit of plasma). Most trauma centers hold two units of either packed red blood cells (with two units of plasma) or two units of LTOWB in the emergency department. This stock is used to initiate transfusion, while the massive hemorrhage protocol is activated from the blood bank.
  2. Patients transferred from another hospital
  3. Children <15 years (in most communities, patients aged 15-18 years are treated at adult trauma centers, and patients in this age group frequently suffer life-threatening injuries, and will therefore be included)
  4. Known prisoners, defined as individuals involuntarily confined or detained in a penal institution (including juvenile detention, involuntary psychiatric commitment, or court-ordered residential substance abuse treatment)
  5. Moribund patients expected to die within 1 hour
  6. Patients who required an ED thoracotomy or received more than 5 consecutive minutes of cardiopulmonary resuscitation (prior to receiving randomized blood products)
  7. Patients with known "do not resuscitate" orders prior to randomization
  8. Patients who refuse the administration of blood products
  9. Individuals with a research "opt out" bracelet.
  10. Greater than 20% total body surface area (TBSA) burns
  11. Suspected inhalation injury victims
  12. Patients who are obviously pregnant on clinical examination or known to be pregnant as provided by the subject or legally authorized representative

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Podwójnie

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Aktywny komparator: LTOWB

Participants randomized to receive (Low Titer O Whole Blood [LTOWB])

Participants will receive Low Titer O Whole Blood administered intravenously or intraosseously.

Aktywny komparator: Components

Participants randomized to receive the component blood products.

Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
6-hour Mortality
Ramy czasowe: First 6 hours after randomization

Participant vital status at 6-hours following randomization (randomization defined as product container is opened for administration to participant)

First 6 hours after randomization

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
24-hour Mortality
Ramy czasowe: First 24 hours after randomization

Participant vital status at 24-hours following randomization

First 24 hours after randomization
Hospital/30-day Mortality
Ramy czasowe: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Participant vital status at hospital discharge or 30-days post randomization (whichever the earlier)

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Incidence of Pre-specified Complications
Ramy czasowe: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

The number of participants experiencing pre-specified complications. Pre-specified complications include: Acute kidney injury; Ventilator-associated pneumonia; Multiorgan failure; Transfusion-related hyperkalemia; Transfusion-related hypocalcemia; Transfusion associated circulatory overload; Acute respiratory distress syndrome; Symptomatic and asymptomatic deep vein thrombosis; Symptomatic and asymptomatic pulmonary embolism; Bleeding after hemostasis requiring intervention; Stroke; Myocardial infarction; Abdominal compartment syndrome; Transfusion-related allergic reactions; Febrile non-hemolytic transfusion reaction; Systemic inflammatory response syndrome; Sepsis; Alloimmunization in women of childbearing age

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Adjudicated Primary Cause of Death
Ramy czasowe: 30-days post randomization

Primary cause of death as reviewed and determined by the study investigators (consensus)

30-days post randomization
Length of Stay (Hospital and Intensive Care Unit)
Ramy czasowe: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Number of hours hospitalized (includes both hospital and intensive care unit time)

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Hospital-, Ventilator- and Intensive Care Unit-free days
Ramy czasowe: 30-days post randomization

Number of days participant was alive and out of the hospital; number of days participant was not on a ventilator; and the number of days the participant was not in the intensive care unit.

30-days post randomization
Incidence of major surgical procedures
Ramy czasowe: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

The proportion of participants undergoing major surgical procedures.

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Time to hemostasis in those undergoing procedures with a hemostatic component
Ramy czasowe: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Time to hemostasis refers to the time that the subject achieved hemorrhage control (anatomic hemostasis and resuscitation complete) following emergency department arrival.

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Number and type of blood products used until hemostasis is achieved and from hemostasis to 24 hours after randomization
Ramy czasowe: First 24 hours after randomization

The number of units and type of blood products (e.g. whole blood, packed red blood cells, platelets, plasma, etc.)

First 24 hours after randomization
Discharge destination
Ramy czasowe: At hospital discharge or 30-days post randomization (whichever the earlier)

Discharge destination will be measured as a categorical variable. Categories will be tallied and compared between the two study arms. Example variables include: discharged to home, discharged to another primary care facility, discharged to hospice, etc.

At hospital discharge or 30-days post randomization (whichever the earlier)
Functional status
Ramy czasowe: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Functional status will be measured by Extended Glasgow Outcome Scale (GOSE). The GOSE is a tool used to measure recovery following brain injury and assists with prediction of long-term rehabilitation. The 8 scoring categories are death, vegetative state, lower severe disability, upper severe disability, lower moderate disability, upper moderate disability, lower good recovery and upper good recovery. A higher GOSE score correlates with better outcome.

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Patient's quality of life
Ramy czasowe: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Quality of life will be measured by the Euroqol Group's EQ-5D quality of life measurement. The EQ-5D is a patient-reported questionnaire assessing health status in terms of five dimensions of health (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression). Lower EQ-5D scores are associated with better outcome.

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Współpracownicy

Śledczy

  • Główny śledczy: Jan Jansen, MBBS, PhD, University of Alabama at Birmingham

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

27 lipca 2023

Zakończenie podstawowe (Rzeczywisty)

4 sierpnia 2026

Ukończenie studiów (Rzeczywisty)

4 sierpnia 2026

Daty rejestracji na studia

Pierwszy przesłany

8 listopada 2022

Pierwszy przesłany, który spełnia kryteria kontroli jakości

28 listopada 2022

Pierwszy wysłany (Rzeczywisty)

6 grudnia 2022

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

22 września 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

18 września 2026

Ostatnia weryfikacja

1 sierpnia 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • IRB-300010517
  • 1UG3HL157401-01A1 (Grant/umowa NIH USA)
  • 1U24HL157310-01A1 (Grant/umowa NIH USA)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .